For Immediate Release
Chicago, IL – May 13, 2022 – Zacks Value Trader is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing stocks in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: (https://www.zacks.com/stock/news/1923561/value-investors-stick-with-the-basics-in-2022)
Value Investors: Stick with the Basics in 2022
Welcome to Episode #281 of the Value Investor Podcast.
- (0:45) – Finding Strong Deals In The Market Sell Off: Stock Screener Criteria
- (8:15) – Tracey’s Top Stock Picks
- (28:20) – Big Takeaways For Your Stock Watchlist: BG, ADM, TWI, PAG, LAD, BZH, TOL, CCRN, AMN, CROX
Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks.
With growth stocks still selling off, many investors might think that there’s value there.
But why buy beaten down growth, when you can buy cheap value stocks with strong fundamentals, including rising earnings estimates?
Don’t look at the past for the deals. Look to the future. There will be new leaders in the market going forward.
It’s time for value stocks to step into the void.
Screening for Top Value Stocks
Investors can find value through the basic fundamentals, like a low P/E and P/S ratios.
Tracey looked for stocks with forward P/Es under 20 and P/S ratios under 1.0.
And you can add the Zacks #1 Rank stocks on top of that. The #1 Ranks are strong buy stocks. They are rare. Out of over 4,000 stocks that Zacks ranks, only about 220 to 230 stocks are the top Zacks Rank of #1.
It usually means the analysts are raising their full year estimates and in this type of market, that’s a huge positive.
Running this screen, it returns 70 stocks. That’s a lot. Just goes to show you, there’s plenty of dirt-cheap stocks out there.
5 Top Ranked Value Stocks
1. Bunge Limited BG
Bunge is the food products giant, who is a leader in oilseed processing. According to the company, it connects farmers to consumers.
Investors have been diving into Bunge all year, and the shares are still up 18.4% year-to-date, but are off 2022 highs.
It’s still cheap even with the shares rallying as Bunge has a forward P/E of 9.2 and pays a dividend of 2%.
Is it too late to buy Bunge or is there further upside?
2. Titan International TWI
Titan International’s tag line says “Titan moves the world.” It makes tires for the agriculture and big equipment industries.
In Q1, Titan’s sales rose 37.8%, which was the highest sales since Q2 2013.
Titan has been a hidden gem in 2022, as shares are up 41% year-to-date. Yet, it’s still cheap with a forward P/E of 9.7.
Should investors hide out in Titan International in 2022?
3. Penske Automotive Group PAG
Penske Automotive is an auto and truck retailer and also owns 28.9% of Penske Transportation, a logistics company. The Street thought 2021 was “peak” earnings in the auto retailers but they were wrong as analysts expect Penske’s 2022 earnings to grow 3.3%.
Penske is dirt cheap with a forward P/E of just 6.8. It also pays a dividend, currently yielding 1.7%.
Shares are up 0.5% year-to-date.
Is Penske being overlooked by the market?
4. Beazer Homes BZH
Beazer Homes is one of the large publicly-traded home builders. Shares have fallen 39% year-to-date.
Beazer Homes is absurdly cheap with a forward P/E of 2.4. Even Beazer insiders know shares are on sale. On May 11, Beazer announced that the Board had authorized a new $50 million share buyback program, replacing the prior one which had $12 million remaining.
Beazer’s earnings are expected to rise 49% in 2022 but the Street expects a slowdown due to rising mortgage rates.
Is Wall Street wrong on Beazer Homes?
5. Cross Country Healthcare CCRN
Cross Country Healthcare specializes in medical staffing, including nurses and physicians.
In 2022, analysts still believe will rise earnings 49.4% to $4.57 from $3.06 last year. But the Street is worried about falling demand and declining rates for travel nurses.
Cross Country Healthcare shares have fallen 42% year-to-date. It’s now dirt-cheap with a forward P/E of 3.5.
Is Cross Country Healthcare a hidden value gem?
What Else do you need to know About Screening for Top Value Stocks in 2022?
Tune into this week’s podcast to find out.
Why Haven’t You Looked at Zacks’ Top Stocks?
Our 5 best-performing strategies have blown away the S&P’s impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligations.
See Stocks Free >>
Tracey Ryniec is the Value Stock Strategist for Zacks.com. She is also the Editor of the Insider Trader and Value Investor services. You can follow her on twitter at @TraceyRyniec and she also hosts the Zacks Market Edge Podcast on iTunes.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; Continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Click here for your free subscription to Profit from the Pros.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Click to get this free report
Penske Automotive Group, Inc. (PAG): Free Stock Analysis Report
Bunge Limited (BG): Free Stock Analysis Report
Beazer Homes USA, Inc. (BZH): Free Stock Analysis Report
Titan International, Inc. (TWI): Free Stock Analysis Report
Cross Country Healthcare, Inc. (CCRN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.